Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 13

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Retinopathy of prematurity

Not yet recruiting

Intranasal Dexmedetomidine for Pain Relief During Retinopathy of Prematurity Screening in Preterm Infants <30 Weeks Gestation Using Standard Drug Combination

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Dexmedetomidine
  • Sponsor:St. Olavs Hospital HF

Conjunctivitis allergic+3

Not yet recruiting

Clinical Trial of Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Blomia tropicalis Allergen Extracts in Patients with Allergic Rhinitis/Rhinoconjunctivitis With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allergen extracts
  • Sponsor:Inmunotek S.L.

Seasonal allergy

Not yet recruiting

Dose-finding study of sublingual immunotherapy with phleum pratense extract (vs sodium chloride) in patients with grass pollen allergic rhinitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Phleum Pratense
  • Sponsor:Asac Pharmaceutical Inmunology S.A.

Giant cell arteritis+1

Not yet recruiting

Diagnostic Accuracy of 68Ga‑FAPI‑46 PET/CT in Patients with Suspected Giant Cell Arteritis and Polymyalgia Rheumatica

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Dry age-related macular degeneration

Not yet recruiting

A study to evaluate the safety and effectiveness of ADX-038 in adults with geographic atrophy caused by age-related macular degeneration.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADX-038
  • Sponsor:Adarx Pharmaceuticals Inc.

Axial spondyloarthritis+1

Not yet recruiting

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Care Arthritis Ltd.

Sjogren's syndrome

Not yet recruiting

A study to evaluate the effect of obinutuzumab on removing specific immune cells in the tissues of patients with Sjögren's syndrome.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Stichting Radboud universitair medisch centrum

Hereditary optic atrophy

Not yet recruiting

A study to evaluate the effectiveness of nicotinamide in patients with Leber's hereditary optic neuropathy who have experienced vision loss within the last 18 months

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Uveal melanoma

Not yet recruiting

A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Replimune Group Inc.

Endocrine ophthalmopathy+1

Not yet recruiting

A study to test if atorvastatin can prevent eye disease in patients newly diagnosed with Graves' disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Skane

Normal tension glaucoma

Not yet recruiting

A Study of Isosorbide Mononitrate for Patients with Normal Tension Glaucoma to Improve Blood Flow to the Optic Nerve

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:University Of Helsinki

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.